Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
€ 8.03
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform is designed and developed to optimize the performance of therapeutic proteins. The company's clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.
Data is available to registered users only
Target Price
Buy
Sell